The following sections were updated in follow-up 1: b3, b4, g3, g6, h2, h6, h10 and h11: h11 correction: b3.Device was used in treatment.The device was not returned for analysis, therefore, the clinical observations cannot be confirmed.However, following controls are in place to mitigate the reported product issue.Additionally, the device history records were reviewed to confirm that the devices passed all applicable in-process and final inspections.Per adelante-s introducer sheath in-process and final inspections, ensures sheaths are inspected for visual, dimensional, and peel functional compliance.Destructive testing sampling plan ansi z 1.4, special level 4, aql 0.40 reduced.Manually break the sheath and hub and verify that the seals split easily without extreme elongation.Also verify that the split cap and seals remain secure and do not break free or loosen from the sheath hub.Manually peel the sheath and verify the sheath peels easily along the sheath body and tip.Per adelante, adelante-s and adelante-s2 sheath extrusion select the extrusion tooling (pin/die) for the part to be extruded.Prior to installing the tooling, measure and inspect the tooling to ensure its suitability for use.For the two score line model sheath tubes: perform spc charting on the peel strength and critical dimensions.This is to be performed on every 100th extruded sheath.Measure the peel strength of the extruded sheath per procedure.The instructions for use (ifu) informs the user: flush sheath with 5cc of saline immediately before peeling sheath away in order to minimize back bleeding.Withdraw sheath and valve over the lead or catheter and from the vessel, while keeping the lead in place.Sharply snap the tabs of valve housing in a plane perpendicular to the long axis of the sheath to split the valve and peel sheath apart while withdrawing from the vessel.Based on the investigation, a capa is not required as findings did not identify a design, labeling or manufacturing non-conformity.In addition, there was no new failure mode identified and the risk remains acceptable.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|